In:
Pediatric Hematology/Oncology and Immunopathology, Fund Doctors, Innovations, Science for Children, Vol. 22, No. 1 ( 2023-02-14), p. 53-61
Kurzfassung:
Nijmegen breakage syndrome (NBS) and ataxia-telangiectasia (AT; Louis–Bar syndrome) are primary immunodeficiencies (PID) associated with chromosome instability and DNA repair defects that predispose individuals to an increased risk of various malignancies. In our study, we retrospectively analyzed clinical characteristics and outcomes of 28 cancer cases in 14 patients with AT and 10 patients with NBS who had been treated at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between January 2007 and December 2022. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The most common type of malignancy was mature B-cell non-Hodgkin lymphoma (B-NHL) (42%), with diffuse large B-cell lymphoma (DLBCL) accounting for 91% of all B-NHL cases. Other cases included T-cell acute lymphoblastic leukemia (ALL) ( n = 3), B-cell ALL ( n = 2), Hodgkin lymphoma ( n = 3), NK/T-cell lymphoma ( n = 1), T-cell lymphoblastic lymphoma ( n = 1), peripheral T- cell lymphoma ( n = 2), medulloblastoma ( n = 1) epithelioid rhabdomyosarcoma ( n = 1), T-cell prolymphocytic leukemia ( n = 2). A total of 4 patients were diagnosed with second malignancies (2 children with AT and 2 children with NBS. The diagnosis of PID was suspected or confirmed before the initiation of cancer therapy in 62% of AT patients and in 100% of NBS patients. Treatment was given in accordance with standard protocols with chemotherapy dose modifications. A total of 93% of patients with AT and 80% of patients with NBS required dose reduction. The level of response was quite high: 81% of patients with AT and 58% of patients with NBS achieved complete remission. According to our data, the use of reduced-dose chemotherapy regimens helps to achieve an acceptable toxicity profile without reducing the overall effectiveness of treatment.
Materialart:
Online-Ressource
ISSN:
2414-9314
,
1726-1708
DOI:
10.24287/1726-1708-2023-22-1-53-61
Sprache:
Unbekannt
Verlag:
Fund Doctors, Innovations, Science for Children
Publikationsdatum:
2023
Permalink
